Trial · NCT01294163

Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery

NCT01294163, Phase 3, Completed, Air Liquide Santé International; results first posted 2015-12-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery. Trials, record NCT01294163. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01294163

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery
NCT number: NCT01294163
Status: Completed
Phases: Phase 3
Enrollment: 509 participants, actual
Lead sponsor: Air Liquide Santé International
Conditions: Coronary Artery Disease, General Anesthetic Drug Allergy, Coronary Artery Bypass Graft Surgery
Interventions: Xenon, Sevoflurane, Propofol
First posted: 2011-02-11
Last updated: 2026-07-22
Results first posted: 2015-12-21

Source ClinicalTrials.gov

Registered outcomes10

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Blood Level of Troponin I	Sampling performed 24 hours after the end of the surgical procedure	Blood level of troponin I measured by a central laboratory
Primary	Log-transformed Blood Level of Troponin I	Sampling performed 24 hours after the end of the surgical procedure	Blood level of troponin I measured by a central laboratory
Secondary	Depth of Anaesthesia	4 hours	On-line monitoring of depth of anaesthesia from bi-spectral electroencephalogram analysis (BIS monitor)
Secondary	Arterial Oxygen Saturation	4 hours	Arterial blood gases
Secondary	Haemodynamic Profile	4 hours	Monitoring of heart rate, arterial blood pressure, central venous pressure.
Secondary	Presence or Absence of Postoperative Delirium	7 days	Confusion Assessment Method
Secondary	Clinical Laboratory Tests	7 days
Secondary	ECG Abnormalities	7 days
Secondary	Vital Signs	7 days
Secondary	Presence of Absence of Adverse Events, Including Myocardial Infarction	7 days

Source ClinicalTrials.gov

Outcomes10

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Blood Level of Troponin I	Sampling performed 24 hours after the end of the surgical procedure	The primary analysis was a non-inferiority comparison between Xenon and Sevoflurane and was performed on the Per Protocol (PP) Set composed of all randomised and treated patients with no major protocol deviations during the study.	ng/mL	LEAST_SQUARES_MEAN
SECONDARY	Depth of Anaesthesia	4 hours
SECONDARY	Arterial Oxygen Saturation	4 hours
SECONDARY	Haemodynamic Profile	4 hours
SECONDARY	Presence or Absence of Postoperative Delirium	7 days
SECONDARY	Clinical Laboratory Tests	7 days
SECONDARY	ECG Abnormalities	7 days
SECONDARY	Vital Signs	7 days
SECONDARY	Presence of Absence of Adverse Events, Including Myocardial Infarction	7 days
PRIMARY	Log-transformed Blood Level of Troponin I	Sampling performed 24 hours after the end of the surgical procedure	The non-inferiority comparison between Xenon and Sevoflurane was repeated using log-transformed blood troponin levels on the PP Set.	ng/mL	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Blood Level of Troponin I	Xenon	2.16	95% Confidence Interval 1.54 to 2.78	ng/mL
Blood Level of Troponin I	Sevoflurane	2.57	95% Confidence Interval 1.96 to 3.18	ng/mL
Log-transformed Blood Level of Troponin I	Xenon	0.30	95% Confidence Interval 0.15 to 0.44	ng/mL
Log-transformed Blood Level of Troponin I	Sevoflurane	0.39	95% Confidence Interval 0.25 to 0.54	ng/mL

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Xenon Including Pilot Patients	178
Overall Study	STARTED	Sevoflurane	165
Overall Study	STARTED	TIVA	166
Overall Study	COMPLETED	Xenon Including Pilot Patients	177
Overall Study	COMPLETED	Sevoflurane	165
Overall Study	COMPLETED	TIVA	163
Overall Study	NOT COMPLETED	Xenon Including Pilot Patients	1
Overall Study	NOT COMPLETED	Sevoflurane	0
Overall Study	NOT COMPLETED	TIVA	3

Source ClinicalTrials.gov

Adverse events297

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Atrial fibrillation	Cardiac disorders	Xenon Including Pilot Patients	55	178
other	Atrial fibrillation	Cardiac disorders	Sevoflurane	43	165
other	Atrial fibrillation	Cardiac disorders	TIVA	37	166
other	Tachycardia	Cardiac disorders	Xenon Including Pilot Patients	14	178
other	Tachycardia	Cardiac disorders	Sevoflurane	7	165
other	Tachycardia	Cardiac disorders	TIVA	14	166
other	Bradycardia	Cardiac disorders	Xenon Including Pilot Patients	12	178
other	Bradycardia	Cardiac disorders	Sevoflurane	9	165
other	Bradycardia	Cardiac disorders	TIVA	13	166
other	Pericardial effusion	Cardiac disorders	Xenon Including Pilot Patients	9	178

1 to 10 of 297Source ClinicalTrials.gov

See all 297 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Xenon Including Pilot Patients
Total, all-cause mortality	Sevoflurane
Total, all-cause mortality	TIVA
Total, other adverse events	Xenon Including Pilot Patients	154	178
Total, other adverse events	Sevoflurane	139	165
Total, other adverse events	TIVA	143	166
Total, serious adverse events	Xenon Including Pilot Patients	30	178
Total, serious adverse events	Sevoflurane	24	165
Total, serious adverse events	TIVA	26	166

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01294163

GET https://conductscience.org/api/trials/v1/NCT01294163/events?page=2

API reference For AI assistants